INNV (InnovAge Holding Corp. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by INNV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-27 | PATRICK T BLAIR | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-07-23 | Meredith Delk | Chief Administrative Officer | A | — | — |
| 2026-07-23 | NICOLE DAMATO | CHIEF LEGAL OFFICER | A | — | — |
| 2026-07-23 | Benjamin C Adams | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-07-17 | NICOLE DAMATO | CHIEF LEGAL OFFICER | F | — | — |
| 2026-07-17 | PATRICK T BLAIR | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-07-02 | MARILYN B TAVENNER | Director | A | — | — |
| 2026-07-02 | JAMES G CARLSON | Director | A | — | — |
| 2026-07-02 | Edward Moore Jr. Kennedy | Director | A | — | — |
| 2026-07-02 | Teresa Sparks | Director | A | — | — |
| 2026-07-02 | RICHARD C ZORETIC | Director | A | — | — |
| 2026-07-02 | John Ellis Bush | Director | A | — | — |
| 2026-07-02 | PATRICIA FONTNEAU | Director | A | — | — |
| 2026-06-08 | Jennifer Browne | President and COO | A | — | — |
| 2026-06-08 | NICOLE DAMATO | CHIEF LEGAL OFFICER | F | — | — |
| 2026-06-08 | PATRICK T BLAIR | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2025-12-02 | PATRICK T BLAIR | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2025-11-17 | MICHAEL ANTHONY SCARBROUGH | President and COO | Sell | — | — |
| 2025-09-02 | PATRICK T BLAIR | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2025-08-18 | NICOLE DAMATO | CHIEF LEGAL OFFICER | F | — | — |
| 2025-07-17 | MICHAEL ANTHONY SCARBROUGH | President and COO | A | — | — |
| 2025-07-17 | NICOLE DAMATO | CHIEF LEGAL OFFICER | A | — | — |
| 2025-07-17 | PATRICK T BLAIR | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-07-02 | RICHARD C ZORETIC | Director | A | — | — |
| 2025-07-02 | PATRICIA FONTNEAU | Director | A | — | — |
| 2025-07-02 | JAMES G CARLSON | Director | A | — | — |
| 2025-07-02 | Edward Moore Jr. Kennedy | Director | A | — | — |
| 2025-07-02 | MARILYN B TAVENNER | Director | A | — | — |
| 2025-07-02 | Teresa Sparks | Director | A | — | — |
| 2025-07-02 | John Ellis Bush | Director | A | — | — |
| 2025-06-09 | NICOLE DAMATO | CHIEF LEGAL OFFICER | F | — | — |
| 2025-06-06 | PATRICK T BLAIR | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2025-06-02 | PATRICK T BLAIR | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2025-05-30 | RICHARD C ZORETIC | Director | Buy | — | — |
| 2025-05-23 | RICHARD C ZORETIC | Director | Buy | — | — |
| 2025-05-20 | RICHARD C ZORETIC | Director | Buy | — | — |
| 2025-05-13 | MICHAEL ANTHONY SCARBROUGH | President and COO | Buy | — | — |
| 2025-03-04 | PATRICK T BLAIR | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2024-12-03 | PATRICK T BLAIR | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2024-11-08 | NICOLE DAMATO | CHIEF LEGAL OFFICER | Sell | — | — |
| 2024-09-18 | NICOLE DAMATO | Chief Legal Officer | Sell | — | — |
| 2024-09-09 | JAMES G CARLSON | Director | A | — | — |
| 2024-09-05 | John Ellis Bush | Director | A | — | — |
| 2024-09-05 | MARILYN B TAVENNER | Director | A | — | — |
| 2024-09-05 | RICHARD C ZORETIC | Director | A | — | — |
| 2024-09-05 | Edward Moore Jr. Kennedy | Director | A | — | — |
| 2024-09-04 | PATRICK T BLAIR | PRESIDENT AND CEO | F | — | — |
| 2024-09-03 | JAMES G CARLSON | Director | A | — | — |
| 2024-09-03 | PATRICIA FONTNEAU | Director | A | — | — |
| 2024-09-03 | Teresa Sparks | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 112,988,070 | — |
| — | 10%+ Owner | 112,988,070 | — |
| — | 10%+ Owner | 112,988,070 | — |
| — | CHIEF EXECUTIVE OFFICER | 751,047 | — |
| — | CHIEF LEGAL OFFICER | 328,711 | — |
| — | CHIEF MEDICAL OFFICER | 220,908 | — |
| — | CHIEF OPERATIONS OFFICER | 201,955 | — |
| — | President and COO | 119,617 | — |
| — | Director | 102,349 | — |
| — | Director | 100,000 | — |
| — | Director | 95,889 | — |
| — | Director | 76,696 | — |
| — | Director | 70,664 | — |
| — | President and COO | 67,842 | — |
| — | Director | 67,665 | — |
| — | Director | 53,696 | — |
| — | Director | 53,696 | — |
| — | Chief Administrative Officer | 42,808 | — |
| — | CHIEF FINANCIAL OFFICER | 17,123 | — |
| — | CEO, President and Director | 9,350 | — |
| — | Chief Financial Officer | 2,000 | — |
| — | Chief Sales and MKTG Officer | 1,875 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INNV quote page; the site-wide leaderboard is on the insider transactions hub.